Scott Palmer

scott-palmer

Scott M. Palmer, MD, MHS

Director, Pulmonary Research
Professor of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine
Vice Chair for Research, Department of Medicine

Website

https://scholars.duke.edu/display/per9358742

Biography

Dr. Palmer leads a successful program of clinical, basic, and translational research in transplantation and advanced lung diseases. He directs the pulmonary research program at the DCRI and serves as Vice Chair for Research in the Department of Medicine.

Palmer has over 150 peer-reviewed publications, received numerous awards, including election into the American Society for Clinical Investigation (ASCI) in 2012, chaired many sessions at national and international meetings, serves regularly on NIH study sections, and is on the editorial board of many prominent journals. He is the Associate Director of the Clinical Research Training Program at Duke and has personally mentored over 40 pre- and post-doctoral trainees, many of whom are now engaged in successful research careers.

Palmer's scientific accomplishments include the first human studies to demonstrate the importance of innate immunity in transplant rejection, and completion of a prospective multicenter study that improved CMV prevention after lung transplantation.

Current lab projects include studying the role of the matrix in the activation of innate immunity in pulmonary transplant rejection, and epithelial injury and repair in the development of toxin induced bronchiolitis obliterans. Translational and human projects include studying predictors of lung transplant survival in the UNOS database, immune monitoring to predict CMV infection and acute rejection after lung transplantation, and the use of novel inhaled antibiotics in lung transplantation. His lab is also using cutting edge whole exome genetic sequencing to identify genetic predictors of transplant rejection.

Palmer leads trials coordinated through the DCRI that study the natural history and investigate new treatments for idiopathic pulmonary fibrosis (IPF), chronic lung transplant rejection, and posttransplant cytomegalovirus infection.